OCON Therapeutics Raises $10M to Enhance Women's Health Solutions

OCON Therapeutics raises $10M in Funding

OCON Therapeutics (Linkedin), a leading health company in Israel, has secured $10M in funding to further develop their innovative drug delivery systems for treating uterine pathologies. With a focus on women's health, OCON Therapeutics aims to provide effective solutions for abnormal and heavy uterine bleeding.

Funding Amount: $10 million

Industry: Pharmaceutical Manufacturing

Employee Count: 11-50

CEO: Keren Leshem (CEO Linkedin)

What OCON Therapeutics needs to buy: OCON Therapeutics is seeking partnerships with research institutions, pharmaceutical companies, and manufacturers to advance their drug delivery systems. Additionally, they require marketing and sales support to reach healthcare providers and patients in need of uterine pathology treatments. Companies specializing in women's health, pharmaceutical manufacturing, and marketing services are ideal partners for OCON Therapeutics' growth and expansion.